Teacher Retirement System of Texas Raises Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Teacher Retirement System of Texas increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 11.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 697,574 shares of the company’s stock after acquiring an additional 69,994 shares during the quarter. Teacher Retirement System of Texas’ holdings in Teva Pharmaceutical Industries were worth $14,091,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Cromwell Holdings LLC raised its stake in shares of Teva Pharmaceutical Industries by 40.3% during the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the period. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries during the second quarter valued at about $41,000. Sound Income Strategies LLC increased its holdings in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the last quarter. JTC Employer Solutions Trustee Ltd purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth about $65,000. Finally, MAI Capital Management raised its position in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after acquiring an additional 697 shares during the period. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, insider Mark Sabag sold 216,892 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the sale, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 622,060 shares of company stock worth $17,076,965. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.5%

NYSE:TEVA opened at $31.83 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $33.42. The stock’s fifty day moving average price is $29.64 and its two-hundred day moving average price is $22.62. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The company has a market cap of $36.51 billion, a P/E ratio of 53.05, a P/E/G ratio of 1.82 and a beta of 0.66.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TEVA shares. Jefferies Financial Group increased their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Bank of America raised their target price on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Barclays started coverage on Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $33.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.